行情

KMPH

KMPH

KemPharm
NASDAQ

实时行情|Nasdaq Last Sale

0.2368
+0.0257
+12.17%
盘后: 0.2360 -0.0008 -0.34% 16:57 04/08 EDT
开盘
0.2100
昨收
0.2111
最高
0.2450
最低
0.2095
成交量
270.89万
成交额
--
52周最高
2.000
52周最低
0.1800
市值
1,200.21万
市盈率(TTM)
-0.2720
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测KMPH价格均价为2.500,最高价位2.500,最低价为2.500。

EPS

KMPH 新闻

更多
  • 收盘:关注疫情发展 美股收高道指涨逾700点
  • 新浪美股 · 50分钟前
  • 机构:本季度股市还有一次逢低买入机会
  • 新浪财经-自媒体综合 · 1小时前
  • 周三黄金期货微涨60美分 白银期货收跌1.8%
  • 新浪美股 · 1小时前
  • 债务迅速增长 全球经济或遭“重挫”
  • 新浪财经-自媒体综合 · 1小时前

所属板块

生物技术和医学研究
+3.08%
制药与医学研究
+2.83%

热门股票

代码
价格
涨跌幅

KMPH 简况

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
展开

微牛提供KemPharm Inc(NASDAQ-KMPH)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的KMPH股票新闻,以帮助您做出投资决策。